29. Off-balance sheet arrangements
Contractual obligations and commitments
On 31 December 2022, we had outstanding obligations for future purchase commitments, which become due as follows:
(thousands of €) |
Total |
Less than |
1 – 3 years |
3 – 5 years |
More than |
|---|---|---|---|---|---|
Purchase commitments |
398,627 |
240,237 |
136,560 |
20,797 |
1,032 |
On 31 December 2021, we had outstanding obligations for future purchase commitments, which become due as follows:
(thousands of €) |
Total |
Less than |
1 – 3 years |
3 – 5 years |
More than |
|---|---|---|---|---|---|
Purchase commitments |
369,937 |
212,065 |
105,947 |
46,426 |
5,499 |
In addition to the tables above, we have a contractual cost sharing obligation related to our collaboration agreement with Gilead for filgotinib. This amounted to €281.6 million on 31 December 2022 (€369.9 million at 31 December 2021), for which we have purchase commitments of €217.3 million at 31 December 2022 (€169.6 million at 31 December 2021) reflected in the tables above.